Donald Downer, MD
Ophthalmology · Orange Park, FLNPI 1588777833
Payments from drug & device makers
Across 181 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$695
- Johnson & Johnson Surgical Vision, Inc.$548
- Bausch & Lomb Americas Inc.$307
- Ocular Therapeutix, Inc.$273
- Tarsus Pharmaceuticals, Inc.$239
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,741100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 37 | $1,140 |
| AbbVie(2 entities) | 36 | $695 |
| Johnson & Johnson Surgical Vision, Inc. | 17 | $548 |
| Bausch & Lomb Americas Inc. | 11 | $307 |
| Ocular Therapeutix, Inc. | 8 | $273 |
| Tarsus Pharmaceuticals, Inc. | 10 | $239 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $208 |
| Kala Pharmaceuticals, Inc. | 4 | $205 |
| Biotissue Holdings Inc. | 1 | $166 |
| Johnson & Johnson Vision Care, Inc. | 3 | $128 |
| Sun Pharmaceutical Industries Inc. | 7 | $113 |
| Amgen(2 entities) | 3 | $96 |
| Novartis | 5 | $91 |
| Dompe US, Inc. | 3 | $88 |
| Oyster Point Pharma, Inc. | 5 | $85 |
| ANI Pharmaceuticals, Inc. | 4 | $71 |
| Omeros Corporation | 4 | $65 |
| Sight Sciences, Inc. | 6 | $44 |
| Harrow Eye, LLC | 2 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Sanofi | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Carl Zeiss Meditec USA, Inc. | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Eyepoint US, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Luxor$147
- INVELTYS$141
- Clareon PanOptix Pro$139
- Tecnis IOL$134
- Clareon$130
- DEXTENZA$100
How this compares
$4,741 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 148 | $139,945 |
| MieboPerfluorohexyloctane/Pf | 56 | $42,934 |
| Loteprednol Etabonate | 156 | $21,403 |
| Difluprednate | 174 | $21,082 |
| XiidraLifitegrast | 15 | $11,803 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $11,536 |
| LumiganBimatoprost | 14 | $11,379 |
| TyrvayaVarenicline Tartrate | 12 | $11,243 |
| Prednisolone Acetate | 301 | $9,763 |
| LotemaxLoteprednol Etabonate | 16 | $7,562 |
| Cyclosporine | 22 | $6,241 |
| MoxifloxacinMoxifloxacin Hcl | 174 | $5,860 |
| EysuvisLoteprednol Etabonate | 12 | $5,791 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $4,094 |
| ValacyclovirValacyclovir Hcl | 82 | $3,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $695 | $162,860200 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $307 | $54,73771 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax | $208 | $28,965172 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $85 | $11,24312 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $205 | $5,79112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Orange Park
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.